Shopping Cart
- Remove All
Your shopping cart is currently empty
trans-Pralsetinib
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).
Catalog No. T10823Cas No. 2097132-93-7
Resource Download
trans-Pralsetinib
Catalog No. T10823Cas No. 2097132-93-7
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $84 | 5 days |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "trans-Pralsetinib"
Regorafenib
Cited
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ , exhibiting both antitumor and anti-angiogenic activity.
- $30
Size
QTY
CitedRegorafenib monohydrate
T1792L1019206-88-2
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β , KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.
- $30
Size
QTY
Lenvatinib mesylate Cited
T8541857890-39-2
Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
- $34
Size
QTY
CitedFedratinib Cited
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
- $45
Size
QTY
CitedLenvatinib Cited
T0520417716-92-8
Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.
- $40
Size
QTY
CitedSelpercatinib Cited
T82222152628-33-4
Selpercatinib (LOXO-292) is a tyrosine kinase inhibitor with antineoplastic properties, displaying IC50 values of 14.0 nM for RET (WT), 24.1 nM for RET (V804M), and 530.7 nM for RET (G810R).
- $30
Size
QTY
CitedRegorafenib Hydrochloride
T8402835621-07-3
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- $30
Size
QTY
Cabozantinib Cited
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
- $39
Size
QTY
CitedAmuvatinib
Cited
T2516850879-09-3
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
- $44
Size
QTY
CitedSGI-7079
T69821239875-86-5
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
- $35
Size
QTY
ON123300
T69201357470-29-1
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ /FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
- $39
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET). |
| Alias | cis-Pralsetinib, cis-BLU-667 |
| Molecular Weight | 533.6 |
| Formula | C27H32FN9O2 |
| Cas No. | 2097132-93-7 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μ L DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μ L DMSO main solution, add 300 μ LPEG300 mix well and clarify, then add 50 more μ L Tween 80, mix well and clarify, then add 600 more μ LddH2O mix well and clarify
main solution, add 300 mix well and clarify, then add 50 more mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy trans-Pralsetinib | purchase trans-Pralsetinib | trans-Pralsetinib cost | order trans-Pralsetinib | trans-Pralsetinib chemical structure | trans-Pralsetinib formula | trans-Pralsetinib molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.